FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 340:1108-1110 April 8, 1999 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

In this issue of the Journal, Martin and colleagues report the success of oral ganciclovir in reducing the risk of cytomegalovirus disease in the initially unaffected eye and other organs of patients with AIDS who have cytomegalovirus retinitis and who are treated with an intraocular ganciclovir implant.¹ These findings confirm a long-held assumption about the value of such adjunctive therapy with oral ganciclovir. The study also hints at new directions for the management of cytomegalovirus retinitis in the era of potent antiretroviral therapy.

The ganciclovir implant offers superior control of the activity of virus within the eye,² but cytomegalovirus retinitis . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.